Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek Revenue Could Double, Reach $90 Mil. In FY 2003, CEO Says

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences expects to double its penetration in both domestic and international infant formula markets by next year, company execs said during a June 6 analysts' call
Advertisement

Related Content

Martek Fiscal 2002 Sales Jump 144.7%; WIC Acceptance Aids Growth
Martek Fiscal 2002 Sales Jump 144.7%; WIC Acceptance Aids Growth
Martek Fiscal 2002 Sales Jump 144.7%; WIC Acceptance Aids Growth
DHA, ARA Benefit Preterm Infants, Research Shows; Formulas On Horizon
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity

Topics

Advertisement
UsernamePublicRestriction

Register

PS094122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel